# HeartFlow, Inc.: Not applicable (device, behavioral) study in CAD - Coronary Artery Disease (500 participants)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | HeartFlow, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care |
| NCT ID | NCT07853716 |
| Phase | Not applicable (device, behavioral) |
| Status | not yet recruiting |
| Conditions | CAD - Coronary Artery Disease |
| Intervention types | device |
| Target enrollment | 500 |
| Site countries | United States |
| Posted | 2026-10-02 |
| Planned start | 2026-11 |
| Event | Newly registered study |
| Event date | 2026-10-02 |

## Why this score
- Industry sponsor (buys outsourced services).
- 500 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07853716). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.